BioCorRx Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BioCorRx Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $797.2K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $7.7K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $89.2K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $213.8K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $48.3K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $122.6K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $240.3K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $376.7K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $657.3K | Apr 16, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $657.3K | Apr 5, 2018 |
| FY2017 | Dec 31, 2016 | $701.8K | Apr 5, 2018 |
| FY2016 | Dec 31, 2015 | $924.7K | Apr 13, 2017 |
| FY2015 | Dec 31, 2014 | $1.17M | Apr 14, 2016 |
| FY2014 | Dec 31, 2013 | $715.0K | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $868.2K | Apr 14, 2014 |
| FY2012 | Dec 31, 2011 | $771.8K | Apr 15, 2013 |
| FY2011 | Dec 31, 2010 | $144.4K | May 18, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $554.8K | Apr 14, 2014 |
| FY2013 | Dec 31, 2012 | $465.7K | Apr 14, 2014 |
| FY2012 | Dec 31, 2011 | $371.3K | Apr 15, 2013 |
| FY2011 | Dec 31, 2010 | ($11.8K) | May 18, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.44M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($5.11M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($3.77M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($4.38M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($5.21M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($3.51M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($6.05M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($6.58M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($29.71M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($5.90M) | Apr 5, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.83M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($5.12M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($3.79M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($4.70M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($5.51M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($7.49M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($5.56M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($4.63M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($2.89M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($2.18M) | Apr 5, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.77M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.48M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $891.1K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.46M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.61M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $4.27M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.13M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $151.8K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $450.7K | Apr 16, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.79M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $3.61M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.88M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $3.41M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $3.74M | Mar 31, 2023 |
| FY2011 | Dec 31, 2011 | $713.6K | May 18, 2012 |
| FY2011 | Dec 31, 2010 | $119.9K | May 18, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.30M) | Mar 31, 2026 |
| FY2025 | Sep 30, 2025 | ($1.45M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($1.10M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($1.85M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($2.04M) | Apr 1, 2024 |
| FY2023 | Sep 30, 2022 | ($1.59M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($3.54M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($2.15M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($2.94M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($1.83M) | Mar 30, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $0 | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $2.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 31, 2022 |
| FY2018 | Dec 31, 2018 | $10.0K | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $305.6K | Apr 5, 2018 |
| FY2015 | Dec 31, 2014 | $487 | Apr 14, 2016 |
| FY2014 | Dec 31, 2013 | $6.7K | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $820 | Apr 14, 2014 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.15M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $385.9K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $388.9K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $766.6K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $820.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.83M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $3.93M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $628.2K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $338.9K | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $470.4K | Apr 5, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.67M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $12.74M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $10.34M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $8.97M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $7.78M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $6.04M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $4.99M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $6.33M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $4.23M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $8.60M | Apr 5, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.22M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($12.12M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($9.82M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($8.08M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($6.96M) | Mar 31, 2023 |
| FY2022 | Dec 31, 2020 | ($4.21M) | Mar 31, 2023 |
| FY2020 | Dec 31, 2019 | ($1.06M) | Mar 31, 2021 |
| FY2020 | Dec 31, 2018 | ($5.71M) | Mar 31, 2021 |
| FY2018 | Dec 31, 2017 | ($3.89M) | Apr 16, 2019 |
| FY2018 | Dec 31, 2016 | ($8.13M) | Apr 16, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $563.2K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 31, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($86.65M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($83.21M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($78.10M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($74.34M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($69.97M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($64.69M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($61.22M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($55.18M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($48.84M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($19.13M) | Apr 5, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2020 | $592.1K | Mar 31, 2022 |
| FY2021 | Dec 31, 2019 | $2.65M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $279.8K | Mar 31, 2021 |
| FY2015 | Dec 31, 2015 | $220.1K | Apr 14, 2016 |
| FY2015 | Dec 31, 2014 | $53.1K | Apr 14, 2016 |
| FY2015 | Dec 31, 2013 | $108.6K | Apr 14, 2016 |
| FY2014 | Dec 31, 2012 | $6.0K | Mar 31, 2015 |
| FY2013 | Dec 31, 2011 | $1.7K | Apr 14, 2014 |
| FY2012 | Dec 31, 2010 | $7.1K | Apr 15, 2013 |
| FY2011 | Dec 31, 2009 | $27.9K | May 18, 2012 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $0 | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $99.9K | Mar 31, 2023 |
| FY2015 | Dec 31, 2015 | $1.86M | Apr 14, 2016 |
| FY2014 | Dec 31, 2014 | $770.3K | Mar 31, 2015 |
| FY2013 | Dec 31, 2013 | $1.13M | Apr 14, 2014 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 24.49M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 13.30M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 8.67M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 7.72M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 6.70M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 5.46M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 5.33M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 2.60M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 2.44M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | 181.80M | Apr 5, 2018 |